
When Placebo Plus Standard of Care Clouds the Signal: Unmasking the “Placebo Problem” in Lupus Clinical Trials
In the evolving landscape of systemic lupus erythematosus (SLE) drug development, high placebo response rates remain a major obstacle to demonstrating the added value of new therapies. Of note, patients in the placebo arm are rarely untreated. They …